Journal of Clinical Immunology

, Volume 28, Issue 4, pp 343–349 | Cite as

Polymorphisms of KIRs Gene and HLA-C Alleles in Patients with Ankylosing Spondylitis: Possible Association with Susceptibility to the Disease

  • Yu-Lian Jiao
  • Chun-Yan Ma
  • Lai-Cheng Wang
  • Bin Cui
  • Jie Zhang
  • Li You
  • Zi-Jiang Chen
  • Jian-Feng Li
  • Yue-Ran Zhao



An emerging body of evidence is accumulating to suggest that killer cell immunoglobulin-like receptors (KIRs) and human leukocyte antigen (HLA) class I ligands contribute to the pathogenesis of diverse kinds of autoimmune diseases. However, the functional effects of their polymorphism remain largely unknown to date. Thus, the present study was undertaken to determine the association of the polymorphisms KIRs gene and HLA-C alleles with the susceptibility to ankylosing spondylitis (AS) by means of polymerase chain reaction/sequence-specific primers for genotyping KIRs from genomic DNA of 119 patients with AS together with 128 healthy donors as a control group.

Results and Discussion

We found that the frequencies of KIR3DS1 and KIR2DL5 were statistically significantly higher in the patient group than those in the control group (P = 0.016 and P = 0.003, respectively). Meanwhile, the percentage of patients, who were carrying two or more of the activating KIRs, was higher than that of control group. With respect to HLA-C alleles, individuals with AS showed an increased frequency of HLA-Cw02. If HLA-C was divided into group 1 or group 2 based on whether there was an asparagine or lysine present at position 80 of the alpha-chain, HLA-C group 2 was more common in subjects with AS compared to control subjects. The genotype 2DS1+/HLA-C lys80+ was more common in subjects with AS. Moreover, the CD69 expression, a NK activation marker, remarkably increased in patient with AS.


In conclusions, this study suggests that KIR3DS1 may severe as AS susceptive genes to trigger continuous injury of arthrosis. The imbalance of activating and inhibitory KIR as well as HLA-C group 1 and group 2 may be the key factor, which influences the pathogenesis of AS. Moreover, KIR2DS1 might associate with the susceptibility of AS by influencing NK cell activity once group 2 HLA-C ligands are present.


Immunoglublin-like receptors human leukocyte antigen spondylitis ankylosing genotyping 



This study was supported by Chinese National Natural Science Foundation grants 30371304 and Shandong Provincial Natural Science Foundation grants yz2006c72 to Dr. Y.R. Zhao.


  1. 1.
    Braun J, Bollow M, Remlinger G, Eggens U, Rudwaleit M, Distler A, Sieper J. Prevalence of pondylarthropathies in HLA-B27 positive and negative blood donors. Arthritis Rheum. 1998;41:58–67.PubMedCrossRefGoogle Scholar
  2. 2.
    Sims AM, Wordsworth BP, Brown MA. Genetic susceptibility to ankylosing spondylitis. Curr Mol Med. 2004;4:13–20.PubMedCrossRefGoogle Scholar
  3. 3.
    Reveille JD, Ball EJ, Khan MA. HLA-B27 and genetic predisposing factors in spondyloarthropathies. Curr Opin Rheumatol. 2001;13:265–72.PubMedCrossRefGoogle Scholar
  4. 4.
    Biron CA, Nguyen KB, Pein GC. Innate immune responses to LCMV infections: natural killer cells and cytokines. Curr Top Microbiol Immunol 2002;263:7–27.PubMedGoogle Scholar
  5. 5.
    Leibson PJ. Signal transduction during natural killer cell activation: inside the mind of a killer. Immunity. 1997;6:655–61.PubMedCrossRefGoogle Scholar
  6. 6.
    Martin AM, Freitas EM, Witt CS, Christiansen FT. The genomic organization and evolution of the natural killer immunoglobulin-like receptor (KIR) gene cluster. Immunogenetics. 2000;51:268–80.PubMedCrossRefGoogle Scholar
  7. 7.
    Steffens U, Vyas Y, Dupont B, Selvakumar A. Nucleotide and amino acid sequence alignment for human killer cell inhibitory receptors (KIR). Tissue Antigens. 1998;51:398–413.PubMedCrossRefGoogle Scholar
  8. 8.
    Shilling HG, Guethlein LA, Cheng NW, Gardiner CM, Rodriguez R, Tyan D, Parham P. Allelic polymorphism synergizes with variable gene content to individualize human KIR genotype. J Immunol 2002;168:2307–15.PubMedGoogle Scholar
  9. 9.
    Sawicki MW, Dimasi N, Natarajan K, Wang J, Margulies DH, Mariuzza RA. Structural basis of MHC class I recognition by natural killer cell receptors. Immunol Rev. 2001;181:52–65.PubMedCrossRefGoogle Scholar
  10. 10.
    Henel G, Singh K, Cui D, Pryshchep S, Lee WW, Weyand CM, Goronzy JJ. Uncoupling of T-cell effector functions by inhibitory killer immunoglobulin-like receptors. Blood. 2006;107:4449–57.PubMedCrossRefGoogle Scholar
  11. 11.
    Mandelboim O, Reyburn HT, Sheu EG, Vales-Gomez M, Davis DM, Pazmany L, Strominger JL. The binding site of NK receptors on HLA-C molecules. Immunity. 1997;6:341–50.PubMedCrossRefGoogle Scholar
  12. 12.
    Moretta A, Vitale M, Bottino C, Orengo AM, Morelli L, Augugliaro R, Barbaresi M, Ciccone E, Moretta L. P58 molecules as putative receptors for major histocompatibility complex (MHC) class I molecules in human natural killer (NK) cells: anti-p58 antibodies reconstitute lysis of MHC class I-protected cells in NK clones displaying different specificities. J Exp Med. 1993;178:597–604.PubMedCrossRefGoogle Scholar
  13. 13.
    Martin MP, Nelson G, Lee JH, Pellett F, Gao X, Wade J, Wilson MJ, Trowsdale J, Gladman D, Carrington M. Cutting edge: susceptibility to psoriatic arthritis: influence of activating killer Ig-like receptor genes in the absence of specific HLA-C alleles. J Immunol. 2002;169:2818–22.PubMedGoogle Scholar
  14. 14.
    Wang S, Zhao YR, Jiao YL, Wang LC, Li JF, Cui B, Xu CY, Shi YH, Chen ZJ. Increased activating killer immunoglobulin-like receptor genes and decreased specific HLA-C alleles in couples with recurrent spontaneous abortion. Biochem Biophys Res Commun. 2007;360:696–701.PubMedCrossRefGoogle Scholar
  15. 15.
    van der Linden S, Valkenburg HA, Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum. 1984;27:361–8.PubMedCrossRefGoogle Scholar
  16. 16.
    Bunce M, O’Neill CM, Barnardo MC, Krausa P, Browning MJ, Morris PJ, Welsh KI. Phototyping: comprehensive DNA typing for HLA-A, B, C, DRB1, DRB3, DRB4, DRB5 & DQB1 by PCR with 144 primer mixes utilizing sequence-specific primer (PCR-SSP). Tissue Antigens. 1995;46:355–67.PubMedCrossRefGoogle Scholar
  17. 17.
    Boyington JC, Sun PD. A structural perspective on MHC class I recognition by killer cell immunoglobulin-like receptors. Mol Immunol. 2001;38:1007–21.CrossRefGoogle Scholar
  18. 18.
    Karlsen TH, Boberg KM, Olsson M, Sun JY, Senitzer D, Bergquist A, Schrumpf E, Thorsby E, Lie BA. Particular genetic variants of ligands for natural killer cell receptors may contribute to the HLA associated risk of primary sclerosing cholangitis. J Hepatol. 2007;46:899–906.PubMedCrossRefGoogle Scholar
  19. 19.
    Parham P. MHC class I molecules and KIRs in human history, health and survival. Nat Rev Immunol. 2005;5:201–14.PubMedCrossRefGoogle Scholar
  20. 20.
    Naumova E, Mihaylova A, Ivanova M, Mihailova S. Impact of KIR/HLA ligand combinations on immune responses in malignant melanoma. Cancer Immunol Immunother 2007;56:95–100.PubMedCrossRefGoogle Scholar
  21. 21.
    Yusa S, Catina TL, Campbell KS. KIR2DL5 can inhibit human NK cell activation via recruitment of Src homology region 2-containing protein tyrosine phosphatase-2 (SHP-2). J Immunol. 2004;172:7385–92.PubMedGoogle Scholar
  22. 22.
    Vilches C, Rajalingam R, Uhrberg M, Gardiner CM, Young NT, Parham P. KIR2DL5, a novel killer-cell receptor with a D0-D2 configuration of Ig-like domains. J Immunol. 2000;164:5797–804.PubMedGoogle Scholar
  23. 23.
    Vilches C, Gardiner CM, Parham P. Gene structure and promoter variation of expressed and nonexpressed variants of the KIR2DL5 gene. J Immunology 2000;165:6416–21.Google Scholar
  24. 24.
    Martin MP, Gao X, Lee JH, Nelson GW, Detels R, Goedert JJ, Buchbinder S, Hoots K, Vlahov D, Trowsdale J, Wilson M, O’Brien SJ, Carrington M. Epistatic interaction between KIR3DS1 and HLA-B delays the progression to AIDS. Nat Genet 2002;31:429–34.PubMedGoogle Scholar
  25. 25.
    Alaez C, Gazit E, Ibarrola B, Yaron M, Livneh A, Avishai O, Gorodezky C. Distribution of HLA-B27 subtypes in ankylosing spondylitis in an Israeli population. Arch Med Res. 2007;38:452–5.PubMedCrossRefGoogle Scholar
  26. 26.
    Cauli A, Dessole G, Nurchis PP, Vacca A, Mameli A, Garau P, Pala R, Passiu G, Mathieu A. The role of HLA-B27 molecules in the pathogenesis of ankylosing spondylitis. Reumatismo. 2002;54:266–71.PubMedGoogle Scholar
  27. 27.
    Lopez-Larrea C, Blanco-Gelaz MA, Torre-Alonso JC, Bruges Armas J, Suarez-Alvarez B, Pruneda L, Couto AR, Gonzalez S, Lopez-Vazquez A, Martinez-Borra J. Contribution of KIR3DL1/3DS1 to ankylosing spondylitis in human leukocyte antigen-B27 Caucasian populations. Arthritis Res Ther. 2006;8:R101.PubMedCrossRefGoogle Scholar
  28. 28.
    Arno R, van der Slik B, Koeleman PC, Verduijn W, Bruining GJ, Roep BO, Giphart MJ. KIR in type 1 diabetes disparate distribution of activating and inhibitory natural killer cell receptors in patients versus HLA-matched control subjects. Diabetes. 2003;52:2638–3642.Google Scholar
  29. 29.
    Fang M, Chen R, Cai Q, Duan S, Lv K, Cheng N, Sun S. Association of HLA genes with ankylosing spondylitis in Han population of eastern China. Scand J Immunol. 2007;65:559–66.PubMedCrossRefGoogle Scholar
  30. 30.
    Carter KW, Pluzhnikov A, Timms AE, Miceli-Richard C, Bourgain C, Wordsworth BP, Jean-Pierre H, Cox NJ, Palmer LJ, Breban M, Reveille JD, Brown MA. Combined analysis of three whole genome linkage scans for Ankylosing Spondylitis. Rheumatology (Oxford). 2007;46:763–71.CrossRefGoogle Scholar
  31. 31.
    Boyton RJ, Altmann DM. Natural killer cells, killer immunoglobulin-like receptors and human leucocyte antigen class I in disease. Clin Exp Immunol. 2007;149:1–8.PubMedCrossRefGoogle Scholar
  32. 32.
    Dupont B, Hsu KC. Inhibitory killer Ig-like receptor genes and human leukocyte antigen class I ligands in haematopoietic stem cell transplantation. Curr Opin Immunol. 2004;16:634–43.PubMedCrossRefGoogle Scholar
  33. 33.
    Boyton RJ, Smith J, Ward R, Jones M, Ozerovitch L, Wilson R, Rose M, Trowsdale J, Altmann DM. HLA-C and killer cell immunoglobulin-like receptor genes in idiopathic bronchiectasis. Am J Respir Crit Care Med. 2006;173:327–33.PubMedCrossRefGoogle Scholar
  34. 34.
    Yawata M, Yawata N, Draghi M, Little AM, Partheniou F, Parham P. Roles for HLA and KIR polymorphisms in natural killer cell repertoire selection and modulation of effector function. J Exp Med. 2006;2003:633–45.CrossRefGoogle Scholar
  35. 35.
    Neisig A, Melief CJ, Neefjes J. Reduced cell surface expression of HLA-C molecules correlates with restricted peptide binding and stable TAP interaction. J Immunol. 1998;160:171–9.PubMedGoogle Scholar
  36. 36.
    McCutcheon JA, Gumperz J, Smith KD, Lutz CT, Parham P. Low HLA-C expression at cell surfaces correlates with increased turnover of heavy chain mRNA. J Exp Med. 1995;181:2085–95.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2008

Authors and Affiliations

  • Yu-Lian Jiao
    • 1
  • Chun-Yan Ma
    • 1
  • Lai-Cheng Wang
    • 1
  • Bin Cui
    • 1
  • Jie Zhang
    • 1
  • Li You
    • 1
  • Zi-Jiang Chen
    • 2
  • Jian-Feng Li
    • 1
  • Yue-Ran Zhao
    • 1
  1. 1.Central Laboratory, Shandong Provincial HospitalShandong UniversityJinanPeople’s Republic of China
  2. 2.Research Center for Reproductive MedicineShandong Provincial Hospital of Shandong UniversityJinanChina

Personalised recommendations